Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and ...

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Local biotech entrepreneurs and investors are seeing signs that the four-year "biotech winter" is finally thawing, though ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

We all know someone waiting on a medical breakthrough. It could be a parent battling a chronic illness, a colleague pushing ...

Biotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make ...

Shares of biotech companies were outpacing the broader market on Thursday. The State Street SPDR S&P Biotech ETF was up 2.7%, compared with the 0.8% gain of the S&P 500. A significant portion of these ...

VanEck Biotech ETF gets a Hold rating as top holdings face low growth, patent cliffs, and rich valuation vs. peers. Click to read my latest analysis of BBH.

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to ...